Cambridge, MA, biotech Tokai Pharmaceuticals pulled off a $97.2 million Wall Street debut, raising the money it needs to get its three-in-one treatment for prostate cancer into late-stage development.
Cambridge, MA's Tokai Pharmaceuticals is joining the IPO queue with eyes on $75 million, cash that would get its triple-threat prostate cancer treatment into Phase III trials.
Just a few weeks after bidding farewell to its longtime CEO, Cambridge, MA-based Tokai Pharmaceuticals has rounded up $35.5 million in Series E cash to push into an expanded mid-stage study of its triple-threat treatment for prostate cancer.
Last week Cambridge, MA-based Tokai Pharmaceuticals revealed that Martin Williams would leave the company without explaining where he was going, Mass High Tech reported. Williams now tells the Boston tech pub that he has taken the top job at Yuma Pharmaceuticals.
Cambridge, MA-based Tokai Pharmaceuticals presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer.
Cambridge, MA-based Tokai Pharmaceuticals has rounded up a $23 million venture round to push its lead treatment for prostate cancer into mid-stage trials. And its board has tapped an experienced
Cambridge, MA-based Tokai Pharmaceuticals has rounded up $12 million in funding as part of a $22 million equity-financing round. Apple Tree Partners, which founded the company, contributed the money.